The verified answer
As of Oct 2026, DEPLOY verifies HistoSonics: 1 model, 14 deployments across 11 regions, $102.0M raised. 5 sources back the record.
CategorySurgical robots
Overview
Plymouth, Minnesota-based medical device company developing the Edison Histotripsy System — a robotically assisted platform using focused ultrasound to non-invasively destroy liver tumors. FDA De Novo clearance October 2023. Raised $102M Series D led by Alpha Wave Ventures, valued at $3.75B. Expanding to kidney, pancreas, prostate applications.
Verified record
- Verified deployments
- 14 deployments on file
- Active incidents
- None on file
Valuation of record
DEPLOY VERIFIEDPriced roundSeries D post-money
Key facts
Founded
CEO
Product
FDA
CE Mark (reported, Jul 2026)
Ownership (Aug 2025)
Funding (reported, unconfirmed)
Valuation (reported, 2026)
Data & sources
Web sources
5
5 sources backing this record.View all →
Models (1)
View all models →HistoSonics on the deployment map
View the global map14 verified deployments across 11 regions, newest verified Jan 2025. Explore where HistoSonics's robots are operating, by place and type.
- operationalEdison Histotripsy System at Cambridge University Hospital →Western Europe · verified Jan 2025
- operationalEdison Histotripsy System at Banner Gateway Medical Center →Arizona · verified Jan 2024
- operationalEdison Histotripsy System at Miami, Florida, USA →Southeast · verified Jan 2024
- operationalEdison Histotripsy System at AdventHealth Altamonte Springs →Florida · verified Jan 2024
- operationalEdison Histotripsy System at Seattle, Washington, USA →West Coast · verified Jan 2024
- operationalEdison Histotripsy System at Chicago, Illinois, USA →Midwest · verified Jan 2024
- operationalEdison Histotripsy System at Austin, Texas, USA →Southwest · verified Jan 2024
- operationalEdison Histotripsy System at Emory Johns Creek Hospital →Georgia · verified Jan 2024
- operationalEdison Histotripsy System at Hoag Memorial Hospital Presbyterian →California · verified Jan 2024
- operationalEdison Histotripsy System at Detroit, MI, USA →Midwest · verified Jan 2024
- operationalEdison Histotripsy System at Boston, Massachusetts, USA →North America · verified Jan 2024
- operationalEdison Histotripsy System at Los Angeles, California, USA →West Coast · verified Jan 2024
View the full HistoSonics deployment record →
Relationships
Current leadership (1)
- Steve Augustine CEOreported, not verified
Safety record
No incidents on record for HistoSonics.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Operator customers (1)
- HistoSonics14 deployments
Recent coverage
HistoSonics in third-party press
Peer companies
- DLR Institute of Robotics and Mechatronics6 models
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- Koninklijke Philips2 models
- LEM Surgical2 models
Mentioned on (9)
Registry pages whose text names HistoSonics.
Companies (1)
Robots and products (1)
Deployments (6)
Edison Histotripsy System at Austin, Texas, USA, Edison Histotripsy System at Chicago, Illinois, USA, Edison Histotripsy System at Los Angeles, California, USA, Edison Histotripsy System at Boston, Massachusetts, USA, Edison Histotripsy System at Detroit, MI, USA, Edison Histotripsy System at Seattle, Washington, USA
People (1)
Financial state
- Total funding
- $102.0M
- Reporting basis
- aggregator_estimate
- Lifecycle stage
- early
- Counterparty risk class
- unknown
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Funding rounds (1)
- Series D2026-06-22
$102M(reported) · $3.8B post
Timeline
Every recorded move in HistoSonics’s history, most recent first: funding rounds, partnerships, acquisitions, supply-chain starts, key hires, and press.
Funding roundSeries D funding round
2026-06-22Series D raising $102000000
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdJul 23, 2026
Added to the verified registry
- Deployment verifiedVerifiedJan 1, 2025
Edison Histotripsy System at Cambridge University Hospital
- Deployment verifiedVerifiedJan 1, 2024
Edison Histotripsy System at Austin, Texas, USA
- Deployment verifiedVerifiedJan 1, 2024
Edison Histotripsy System at Miami, Florida, USA
- Deployment verifiedVerifiedJan 1, 2024
Edison Histotripsy System at AdventHealth Altamonte Springs
Sources (5)
- https://histosonics.com/
- https://www.massdevice.com/histosonics-edison-histotripsy-fda-kidney-tumors/
- https://histosonics.com/histosonics-secures-102m-series-d-financing/
- https://www.massdevice.com/histosonics-stake-acquired-2b-investor-syndicate/
- https://www.businesswire.com/news/home/20250807749442/en/HistoSonics-Announces-%242.25B-Acquisition-by-Consortium-of-Top-Tier-Investors
Common questions
What is HistoSonics?
What does HistoSonics make?
Is HistoSonics publicly traded?
Who competes with HistoSonics?
Who is the CEO of HistoSonics?
How can I invest in HistoSonics?
How much funding has HistoSonics raised?
Who owns HistoSonics?
Where does HistoSonics operate robots?
How many robots has HistoSonics deployed?
Is HistoSonics a top robotics company?
When was HistoSonics founded?
Is HistoSonics safe?
Methodology: Verified · 5 sources (no primary) · last reviewed 2026-10-21
Verification posture
Verified
Low confidence
Review state
Stable
Last reviewed 2026-10-21
Sources by quality tier
- 5
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for HistoSonics.Peer companies
- DLR Institute of Robotics and Mechatronics6 models
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- Koninklijke Philips2 models
- LEM Surgical2 models
In the press
Recent coverage mentioning HistoSonics from third-party publications. Automatically surfaced; not part of the verified registry record.
HistoSonics Secures $102M Series D Financing
$102M Series D led by Alpha Wave Ventures. FDA De Novo cleared Edison system for liver tumor histotripsy. $3.75B valuation.
New Financing Values HistoSonics at $3.75B
HistoSonics valued at $3.75B in latest financing with participation from Yosemite and other strategic investors.
Machine-readable surfaces
- Markdown mirror: /companies/histosonics.md
- RSS feed: /companies/histosonics/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/fffa2127-5d46-4965-b510-cf96161154f0
- Revision history: /companies/histosonics/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- DLR Institute of Robotics and Mechatronics6 models
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- Koninklijke Philips2 models
- LEM Surgical2 models
Video
Histotripsy uses very high amplitude and short pulses (microseconds) of focused ultrasound to induce and control acoustic cavitation in the form of a histotrips
Mike Blue, President, CEO of HistoSonics, Inc. For more, visit: www.cednc.org/lsc
Learn more at www.gshealth.org
https://www.gshealth.org/robotic-surgery
In this episode of The Innovation Frontier, we step into the operating room to tell the story of HistoSonics, a company trying to change how tumors are treated
The Latest News in technology you definitely don't want to MISS this 🤯 In this video you’ll discover, Fi's AI-powered dog collar that lets you monitor your pe
Heat Index
Category contender75/100
A composite of competitive footprint, funding, press velocity, active partnerships, and supply-chain edges. Different from the Intelligence score below (which is per-form-factor productization). Non-robotics companies cap at 25.
Reality vs attention
HistoSonics draws attention at the 28th percentile but verifies reality at the 94th percentile among surgical robots. Hype Gap -66.5, 43rd widest among surgical robots.
6-month trend
Analysis
Clean safety record across 14 verified deployments. Strong deployment footprint with 14 operational sites across 14 countries. Limited public visibility and press coverage relative to peers.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Oct 21, 2026